Skip to Main Content

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Conditions

Breast - Female

Phase I

What is the purpose of this trial?

This study is being conducted to examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer, and to find the highest dose of the drug that can be given without unacceptable side effects. Other goals of the trial are to find out if SGN-LIV1A has any antitumor effects, to learn about the pharmacokinetics of SGN-LIV1A, and to explore the relationship between antigen expression and SGN-LIV1A effects.

  • Trial with
    Seattle Genetics, Inc.
  • Start Date
    06/16/2022
  • End Date
    07/31/2022

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    07/12/2022
  • Study HIC
    #1311013056